FDA-cleared profile

ADAS 3D

Adas3D Medical S.L · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.

Clinical role
Cardiac image post-processing and myocardial-scar assessment for clinical review and EP planning.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Heart; myocardial scar and cardiovascular structures
Key limitation
Keep in mind: The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Heart; myocardial scar and cardiovascular structures Input: DICOM enhanced cardiovascular MR and CT angiography images.
  • Who uses it?Intended users: Qualified cardiologists, electrophysiologists, radiologists, and trained technicians.
  • What does the software produce?Output: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.
  • What is its most important limitation?Key limitation: The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.

Clinical takeaway. Clinical role: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.

Evidence takeaway. Evidence from the reviewed source record: K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Cardiac image post-processing and myocardial-scar assessment for clinical review and EP planning.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM enhanced cardiovascular MR and CT angiography images.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Cardiology, electrophysiology, and radiology workflows involving cardiovascular MR and CT.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified cardiologists, electrophysiologists, radiologists, and trained technicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K240791 FDA evidence package for ADAS 3D

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationHeart; myocardial scar and cardiovascular structures
  • Scopeexact submission
  • Tested versionADAS 3D
  • IndependenceSponsor or vendor study

K240791

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K240791 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM enhanced cardiovascular MR and CT angiography images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K240791: ADAS 3D

  2. Routing

    Source context, not route validation: The FDA package describes DICOM enhanced MR and CT input and export in industry-standard formats supported by catheter-navigation systems.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K240791: ADAS 3D

  3. AI processing

    Source context, not route validation: The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K240791: ADAS 3D

  4. Returned objects

    Source context, not route validation: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K240791: ADAS 3D

  5. Viewer/worklist/report

    Unresolved route: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K240791: ADAS 3D

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM enhanced MR and CT input and export in industry-standard formats supported by catheter-navigation systems.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by qualified cardiologists, electrophysiologists, radiologists, and trained technicians. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K240791.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K240791.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes DICOM enhanced MR and CT input and export in industry-standard formats supported by catheter-navigation systems.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K240791.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240791
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Heart; myocardial scar and cardiovascular structures
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-09-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. Two PubMed records name ADAS 3D but do not identify the tested software version or K240791; the remaining records are generic cardiac-imaging evidence, other products, or unlinked trials. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K240791: ADAS 3D

    U.S. Food and Drug Administration - Published 2024-09-09 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Adas 3D model card (K240791)

    American College of Radiology - Published 2026-07-08 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K240791 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253969

ADAS 3D

Adas3D Medical S.L.

Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Heart; myocardial scar and cardiac structures
Decision
2026-06-29
FDA-cleared K254016

MI View&GO

Siemens Medical Solutions USA, Inc.

Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Decision
2026-02-10
FDA-cleared K252634

Imagine® Enterprise Suite

Softlink International Private Limited

Authorized purpose: Imagine Enterprise Suite receives, stores, shares, visualizes, quantifies, and processes images from multiple modalities; MPXA-2000 supports coronary-angiography calculation with automated vessel contours that require review and editing.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Cardiac and coronary anatomy plus multi-modality clinical studies
Decision
2026-01-16
FDA-cleared K250330

3mensio Workstation

Pie Medical Imaging BV

3mensio Workstation is standalone medical-image analysis software for advanced visualization and quantitative analysis of cardiovascular structures. It supports CT, X-ray angiography, and two- and three-dimensional ultrasound DICOM data for planning and sizing cardiovascular interventions, postoperative evaluation, coronary measurements, and calcium scoring.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Heart/Cardiovascular
Decision
2025-11-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history